Sedivention develops a medical device for an outpatient, minimally invasive interventional therapy targeting obesity. This one-time cryo-ablation procedure disrupts the vagus nerve trunks responsible for hunger signaling. The therapy aims to achieve a long-term reduction in the feeling of hunger for patients.
Funding
€3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity is a growing global health crisis, affecting a significant portion of the adult population and contributing to over 400,000 deaths annually in the US alone. Traditional obesity treatments often carry significant risks and side effects, highlighting the need for less invasive and more effective interventions. Current therapies may not provide a long-term solution for weight management.
Solution
Sedivention offers a minimally invasive cryo-ablation therapy targeting the gastric trunks of the vagus nerve to reduce hunger signals and facilitate long-term weight loss. The outpatient procedure involves a single intervention designed to minimize risks and side effects associated with traditional obesity treatments. A catheter is inserted, a balloon is positioned in the stomach, cryo-ablation of the gastric trunks of the vagus nerve is performed, the balloon is deflated, and the catheter is removed. This process reduces the feeling of hunger in the long term and permanently.
Target Audience
The primary target audience includes individuals suffering from obesity and seeking a minimally invasive, long-term weight loss solution, as well as physicians specializing in interventional treatments for obesity.
Features
- Minimally invasive cryo-ablation procedure
- Outpatient interventional treatment
- Single, one-time intervention
- Long-term slimming effect
- Catheter-based delivery system
- Balloon positioning for targeted cryo-ablation